Literature DB >> 29779041

The potential importance of myeloid-derived suppressor cells (MDSCs) in the pathogenesis of Alzheimer's disease.

Antero Salminen1, Kai Kaarniranta2,3, Anu Kauppinen4.   

Abstract

The exact cause of Alzheimer's disease (AD) is still unknown, but the deposition of amyloid-β (Aβ) plaques and chronic inflammation indicates that immune disturbances are involved in AD pathogenesis. Recent genetic studies have revealed that many candidate genes are expressed in both microglia and myeloid cells which infiltrate into the AD brains. Invading myeloid cells controls the functions of resident microglia in pathological conditions, such as AD pathology. AD is a neurologic disease with inflammatory component where the immune system is not able to eliminate the perpetrator, while, concurrently, it should prevent neuronal injuries induced by inflammation. Recent studies have indicated that AD brains are an immunosuppressive microenvironment, e.g., microglial cells are hyporesponsive to Aβ deposits and anti-inflammatory cytokines enhance Aβ deposition. Immunosuppression is a common element in pathological disorders involving chronic inflammation. Studies on cancer-associated inflammation have demonstrated that myeloid-derived suppressor cells (MDSCs) have a crucial role in the immune escape of tumor cells. Immunosuppression is not limited to tumors, since MDSCs can be recruited into chronically inflamed tissues where inflammatory mediators enhance the proliferation and activation of MDSCs. AD brains express a range of chemokines and cytokines which could recruit and expand MDSCs in inflamed AD brains and thus generate an immunosuppressive microenvironment. Several neuroinflammatory disorders, e.g., the early phase of AD pathology, have been associated with an increase in the level of circulating MDSCs. We will elucidate the immunosuppressive armament of MDSCs and present evidences in support of the crucial role of MDSCs in the pathogenesis of AD.

Entities:  

Keywords:  Aging; Alzheimer; Hypoxia; NF-κB; Neuroinflammation; Senescence

Mesh:

Substances:

Year:  2018        PMID: 29779041     DOI: 10.1007/s00018-018-2844-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  224 in total

1.  Diclofenac, a selective COX-2 inhibitor, inhibits DMH-induced colon tumorigenesis through suppression of MCP-1, MIP-1α and VEGF.

Authors:  Jasmeet Kaur; S N Sanyal
Journal:  Mol Carcinog       Date:  2011-01-25       Impact factor: 4.784

2.  Arginase-1 is expressed exclusively by infiltrating myeloid cells in CNS injury and disease.

Authors:  Andrew D Greenhalgh; Rosmarini Passos Dos Santos; Juan Guillermo Zarruk; Christopher K Salmon; Antje Kroner; Samuel David
Journal:  Brain Behav Immun       Date:  2016-04-25       Impact factor: 7.217

3.  Innate immune CD11b+Gr-1+ cells, suppressor cells, affect the immune response during Theiler's virus-induced demyelinating disease.

Authors:  Jenna L Bowen; Julie K Olson
Journal:  J Immunol       Date:  2009-11-04       Impact factor: 5.422

4.  Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease.

Authors:  Julius Popp; Michael Bacher; Heike Kölsch; Carmen Noelker; Oliver Deuster; Richard Dodel; Frank Jessen
Journal:  J Psychiatr Res       Date:  2008-11-26       Impact factor: 4.791

5.  Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent.

Authors:  Yi-Jun Liu; Da-Wen Guo; Li Tian; De-Shu Shang; Wei-Dong Zhao; Bo Li; Wen-Gang Fang; Li Zhu; Yu-Hua Chen
Journal:  Neurobiol Aging       Date:  2010-02       Impact factor: 4.673

6.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

Review 7.  Neuroinflammation in Alzheimer's disease.

Authors:  Michael T Heneka; Monica J Carson; Joseph El Khoury; Gary E Landreth; Frederic Brosseron; Douglas L Feinstein; Andreas H Jacobs; Tony Wyss-Coray; Javier Vitorica; Richard M Ransohoff; Karl Herrup; Sally A Frautschy; Bente Finsen; Guy C Brown; Alexei Verkhratsky; Koji Yamanaka; Jari Koistinaho; Eicke Latz; Annett Halle; Gabor C Petzold; Terrence Town; Dave Morgan; Mari L Shinohara; V Hugh Perry; Clive Holmes; Nicolas G Bazan; David J Brooks; Stéphane Hunot; Bertrand Joseph; Nikolaus Deigendesch; Olga Garaschuk; Erik Boddeke; Charles A Dinarello; John C Breitner; Greg M Cole; Douglas T Golenbock; Markus P Kummer
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

Review 8.  Alzheimer's disease: A matter of blood-brain barrier dysfunction?

Authors:  Axel Montagne; Zhen Zhao; Berislav V Zlokovic
Journal:  J Exp Med       Date:  2017-10-23       Impact factor: 14.307

9.  HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape.

Authors:  Jinfeng Li; Jiajia Sun; Ruiming Rong; Long Li; Wenjun Shang; Dongkui Song; Guiwen Feng; Feifei Luo
Journal:  Oncotarget       Date:  2017-06-28

10.  Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology.

Authors:  Kuti Baruch; Neta Rosenzweig; Alexander Kertser; Aleksandra Deczkowska; Alaa Mohammad Sharif; Amit Spinrad; Afroditi Tsitsou-Kampeli; Ayelet Sarel; Liora Cahalon; Michal Schwartz
Journal:  Nat Commun       Date:  2015-08-18       Impact factor: 14.919

View more
  8 in total

1.  In Situ Deployment of Engineered Extracellular Vesicles into the Tumor Niche via Myeloid-Derived Suppressor Cells.

Authors:  Silvia Duarte-Sanmiguel; Ana Panic; Daniel J Dodd; Ana Salazar-Puerta; Jordan T Moore; William R Lawrence; Kylie Nairon; Carlie Francis; Natalie Zachariah; William McCoy; Rithvik Turaga; Aleksander Skardal; William E Carson; Natalia Higuita-Castro; Daniel Gallego-Perez
Journal:  Adv Healthc Mater       Date:  2021-10-27       Impact factor: 9.933

2.  Transcriptional re-programming in rat central nervous system two weeks after burn trauma: the impact of nephrilin treatment on the expression of oxidative stress-related genes.

Authors:  Desmond D Mascarenhas
Journal:  Scars Burn Heal       Date:  2020-08-11

3.  Eriodictyol and Homoeriodictyol Improve Memory Impairment in Aβ25-35-Induced Mice by Inhibiting the NLRP3 Inflammasome.

Authors:  Pengli Guo; Mengnan Zeng; Shengchao Wang; Bing Cao; Meng Liu; Yuhan Zhang; Jufang Jia; Qinqin Zhang; Beibei Zhang; Ru Wang; Xiaoke Zheng; Weisheng Feng
Journal:  Molecules       Date:  2022-04-12       Impact factor: 4.927

Review 4.  ER stress activates immunosuppressive network: implications for aging and Alzheimer's disease.

Authors:  Antero Salminen; Kai Kaarniranta; Anu Kauppinen
Journal:  J Mol Med (Berl)       Date:  2020-04-11       Impact factor: 4.599

Review 5.  The Yin and Yang of Myeloid Derived Suppressor Cells.

Authors:  Snehil Budhwar; Priyanka Verma; Rachna Verma; Sangeeta Rai; Kiran Singh
Journal:  Front Immunol       Date:  2018-11-28       Impact factor: 7.561

6.  Functional alterations of myeloid cells during the course of Alzheimer's disease.

Authors:  Aaron D Thome; Alireza Faridar; David R Beers; Jason R Thonhoff; Weihua Zhao; Shixiang Wen; Belen Pascual; Joseph C Masdeu; Stanley H Appel
Journal:  Mol Neurodegener       Date:  2018-11-13       Impact factor: 14.195

Review 7.  Roles of Gut Microbiota in the Regulation of Hippocampal Plasticity, Inflammation, and Hippocampus-Dependent Behaviors.

Authors:  Wen Tang; Zhaoyou Meng; Ning Li; Yiyan Liu; Li Li; Dongfeng Chen; Yang Yang
Journal:  Front Cell Infect Microbiol       Date:  2021-01-27       Impact factor: 5.293

Review 8.  Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.

Authors:  Emile J Clappaert; Aleksandar Murgaski; Helena Van Damme; Mate Kiss; Damya Laoui
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.